Processa Pharmaceuticals Inc（PCSA）财务数据PCSAProcessa Pharmaceuticals Inc

Evaluating the bottom line, Processa Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -464.20%, provide a clear picture of how effectively PCSA converts its operational activities into shareholder value.

In the context of the broader market, PCSA competes directly with industry leaders such as BGMS and LIMN. With a market capitalization of $8.15M, it holds a leading position in the sector. When comparing efficiency, PCSA's gross margin of N/A stands against BGMS's 23.51% and LIMN's N/A. Such benchmarking helps identify whether Processa Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Processa Pharmaceuticals has consistently reported negative net income, with Q2 2026 showing a loss of -3,265,494 USD. The company has a current ratio of 0.87, indicating liquidity issues as it has more current liabilities than current assets.